Somewhat Positive Media Coverage Somewhat Unlikely to Affect Tonix Pharmaceuticals (TNXP) Stock Price

News coverage about Tonix Pharmaceuticals (NASDAQ:TNXP) has been trending somewhat positive on Sunday, according to Accern. The research firm identifies positive and negative media coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tonix Pharmaceuticals earned a daily sentiment score of 0.10 on Accern’s scale. Accern also assigned headlines about the company an impact score of 45.8908515227664 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Here are some of the headlines that may have effected Accern Sentiment’s rankings:

Shares of Tonix Pharmaceuticals (TNXP) traded down $0.01 during trading on Friday, reaching $3.80. 30,397 shares of the company’s stock were exchanged, compared to its average volume of 60,810. Tonix Pharmaceuticals has a twelve month low of $2.85 and a twelve month high of $9.40. The firm has a market cap of $29.64, a price-to-earnings ratio of -0.80 and a beta of 2.92.

A number of research analysts have issued reports on the stock. Aegis restated a “buy” rating on shares of Tonix Pharmaceuticals in a research note on Friday, December 1st. ValuEngine lowered shares of Tonix Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $8.33.

In other news, Director Ernest Mario sold 36,967 shares of the company’s stock in a transaction on Thursday, December 21st. The shares were sold at an average price of $3.51, for a total value of $129,754.17. Following the sale, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $35,100. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 48,934 shares of company stock worth $172,496 over the last ninety days. Insiders own 4.00% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.com-unik.info/2018/01/14/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-tonix-pharmaceuticals-tnxp-stock-price.html.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.

Insider Buying and Selling by Quarter for Tonix Pharmaceuticals (NASDAQ:TNXP)

What are top analysts saying about Tonix Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Tonix Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit